Article citationsMore>>

U.S. Food and Drug Administration (2019) Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail. Clinical Trial No. NCT01270971.
https://clinicaltrials.gov/study/NCT01270971?term=NCT01270971&rank=1

has been cited by the following article:

• TITLE: A Dual-Standard Reversed-Phase HPLC-UV Method for the Simultaneous Identification, Assay, and Impurities Analysis of Phenylboronic Acid: Using 4-Methoxyphenyl Boronic Acid as a Model Compound

  AUTHORS: Weijiang Ying, Maria Castelo, Jiangwei Li, Frank Wu

  KEYWORDS: Identification, Assay, Impurities, RP-HPLC-UV Analysis of Phenylboronic Acid, Dual-Standard

  JOURNAL NAME: American Journal of Analytical Chemistry, Vol.17 No.5, May 28, 2026

  ABSTRACT: Boronic acids (BAs) are versatile building blocks in organic synthesis and the pharmaceutical industry. A dual-standard reverse phase (RP) HPLC-UV method was developed for the simultaneous identification (as monomer), assay (as monomer), and impurities analysis of phenylboronic acid (PBA), using 4-methoxyphenyl boronic acid (4-MPBA) as a model compound. The method utilizes an Ascentis? Express 90 ? ES-Cyano column with 0.025% TFA in both mobile phases (A: water, B: methanol). It employs a simple gradient with an injection volume of 10 μL and a flow rate of 0.8 mL/min. This QC-friendly, single-sequence method achieves baseline separation of the analyte and its impurities. By utilizing a stable, readily available bromo-analog surrogate for quantitation, it bypasses the need for a single-component primary BA reference standard.